Organization
Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY
67 abstracts
Abstract
Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.Org: NYU Langone Health, New York, NY, Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Augusta University, Augusta, GA, Bio-Path Holdings, Inc., Bellaire, TX,
Abstract
It takes a village: The impact of social and environmental factors on cervical cancer screening.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Weill Cornell Medical College University,
Abstract
Beneath the surface: Exploring stress and bias in cervical cancer screening compliance.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Weill Cornell Medical College University,
Abstract
Effect of daratumumab on light chain reduction in newly diagnosed multiple myeloma with light chain cast nephropathy.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Frequency of certain germline polymorphisms among ethnicities and adverse drug reaction risk associated with colorectal cancer therapies.Org: OneOme, LLC, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, NewYork-Presbyterian Hospital,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
Feasibility of universal breast cancer risk assessment in a diverse, publicly insured obstetrician gynecology clinic.Org: Weill Cornell Medical College University, New York, NY, New York Medical College - Saint Michael's Medical Center, Valhalla, NY, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study.Org: Dana-Farber Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Mayo Clinic, Massachusetts General Hospital, Stanford Comprehensive Cancer Institute,
Abstract
Assessing barriers to prostate cancer clinical trial participation among Black and African Americans: A multi-perspective qualitative study.Org: David Geffen School of Medicine at UCLA, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Sandra and Edward Meyer Cancer Center, The Pennsylvania Prostate Cancer Coalition, Tisch Cancer Institute,
Abstract
The effect of resting dendritic cells on overall survival in the hepatocellular carcinoma tumor microenvironment.Org: Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital, Royal Oak, MI, NYU Langone Health, New York, NY, New York, NY,
Abstract
Cardiovascular events in patients receiving immuno-oncology agents, in phase I clinical trials: CAVIO study.Org: Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, University of Milano, European Institute of Oncology, Division of Early Drug Development, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy,
Abstract
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).Org: University of Texas Southwestern Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Wake Forest Baptist Health,
Abstract
Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Division of Hematology & Medical Oncology, NewYork-Presbyterian Hospital, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College University,
Abstract
IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.Org: Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany, German Center of Lung Research, Genentech Inc., Stanford University School of Medicine/Stanford Cancer Institute,
Abstract
Assessing mail-in cryopreservation for fertility preservation.Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Shady Grove Fertility Reproductive Science Center, Departments of Urology and Epidemiology & Biostatistics, Fellow Health, San Leandro, CA, Yale Medicine,
Abstract
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Division of Breast Surgery,
Abstract
Prognostic value of tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer (BC): A focus on inflammatory BC.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Northwestern University, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Washington University in St. Louis,
Abstract
Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Weill Cornell Medicine/New York Presbyterian Hospital,
Abstract
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Massachusetts General Hospital, Boston Pharmaceuticals,
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
Hereditary breast and ovarian cancer syndrome: A misnomer?Org: New York Medical College - Saint Michael's Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.Org: Jazz Pharmaceuticals, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Dana-Farber Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Guardant Health, Inc., Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
Melanomas lacking HLA class I expression and response to checkpoint inhibitor.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value.Org: Creatv MicroTech, Inc., Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Fox Chase Cancer Center, Greenebaum Comprehensive Cancer Center, Mayo Clinic,
Abstract
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.Org: Wilmot Cancer Institute, University of Rochester Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center,
Abstract
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).Org: Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH,
Abstract
Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC).Org: Harvard Medical School, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center, Houston, TX,
Abstract
Phase II study of telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, University of Pennsylvania, Weill Cornell Medical College University, University of Pennsylvania Health System,
Abstract
SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).Org: Children's Hospital of Philadelphia, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Pediatric Oncology Branch, Clinical Center National Institutes of Health, Clinical Center National Institutes of Health, NIH / NCI,
Abstract
Impact of imaging frequency on progression free survival in Alliance clinical trials enrolling patients with untreated follicular lymphoma.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Mayo Clinic, Emory University, Atlanta, GA, USA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Vermont Cancer Center,
Abstract
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?Org: Weill Cornell Medicine - Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Memorial Sloan Kettering Cancer Center,
Abstract
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).Org: Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York-Presbyterian Hospital, The Tisch Cancer Institute,
Abstract
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.Org: BC Cancer-Vancouver Centre, Vancouver Prostate Centre, Tulane Cancer Center, Gustave Roussy Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Association of the Duffy-null allele and endometrial cancer characteristics: An effort to explore racial disparity in Black women with endometrial cancer.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Cornell University, Morehouse School of Medicine, NewYork-Presbyterian/Weill Cornell Medical Center,
Abstract
Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, CTC Core Facility, Lurie Cancer Center,
Abstract
Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Queens College, The City University of New York, Plantable, Johns Hopkins Hospital, Sandra and Edward Meyer Cancer Center,
Abstract
The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations.Org: Moffitt Cancer Center, AstraZeneca, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers.Org: AffyImmune Therapeutics, Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Weill Medical College of Cornell University/NewYork-Presbyterian Hospital, NYU Langone Health, New York, NY,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?Org: Weill Cornell Medicine - Qatar, Doha, Qatar, Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, University College Dublin Medical School,
Abstract
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,
Abstract
Lynch screening and genetic testing in endometrial cancer in a diverse population.Org: NewYork-Presbyterian Brooklyn Methodist Hospital, SUNY Downstate Medical Center, Brooklyn, NY, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Patient characteristics associated with psychosocial distress about end-of-life.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Prognosis and risk of suicide after cancer diagnosis.Org: Columbia University Medical Center, Columbia University - Mailman School of Public Health, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Presbyterian - Columbia, Columbia College of Physicians and Surgeons, New York, NY,
Abstract
Digital cancer genetic risk assessment in a gynecologic oncology clinic.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York, NY, Ambry Genetics, Aliso Viejo, CA, Weill Cornell Medical College University,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.Org: Moffitt Cancer Center and Research Institute, Southwest Oncology Group Statistical Center, UPMC Hillman Cancer Center, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
The human connection: Oncologist characteristics that facilitate therapeutic bonding among Latino patients with advanced cancer.Org: City of Hope National Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
ctDNA detection before and during systemic therapy for inflammatory breast cancer.Org: Natera, Inc., Natera Inc., Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Rutgers Cancer Institue of New Jersey, Baylor College of Medicine,
Abstract
Prognostic value of TP53 mutation status in metastatic triple-negative and hormone receptor-positive breast cancer using cell-free DNA genomic profiling.Org: Mass General Brigham-Salem Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Correlation of micronuclei formation in circulating stromal cells with their PD-L1 expression and predicts for poorer clinical outcomes in metastatic breast cancer.Org: Creatv MicroTech, Inc., Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Fox Chase Cancer Center, Mayo Clinic, Greenebaum Comprehensive Cancer Center,
Abstract
A pilot study evaluating somatic mutational burden and signatures among endometrial cancer patients: Is there prognostic benefit to whole genome sequencing?Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Nykode Therapeutics, Cornell University, Morehouse School of Medicine,
Abstract
Cure-PROs: Next-generation targeted protein degraders.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, MRP Pharma LLC, Chapel Hill, NC, Consultant,
Abstract
Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort.Org: Fortis Cancer Institute, Sir H N Reliance Foundation Hospital and Research Centre, BALCO Medical Center, Fortis Hospital Mulund, Datar Cancer Genetics,
Abstract
RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, BostonGene, Corp., University of Texas MD Anderson Cancer Center,
Abstract
High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.Org: Weill Cornell Medical College University, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, NewYork-Presbyterian/Weill Cornell Medical Center, Joan and Sanford I Weill Medical College of Cornell University, NYP/Columbia,
Abstract
Genetic counseling and testing for epithelial ovarian cancer in a diverse patient population.Org: NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn ImmunoTherapeutics, SUNY Downstate Medical Center, Brooklyn, NY, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Exploring the reproductive and sexual health concerns of young adults with cancer.Org: NYP/Columbia, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York, NY, Children’s National Medical Center, Washington, DC, DC,
Abstract
Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,
Abstract
A NOVEL APPROACH FOR MIXED-METHODS RESEARCH USING LANGUAGE LEARNING MODELS: A REPORT USING PATIENTS’ PERSPECTIVES ON BARRIERS TO HIP AND KNEE REPLACEMENTOrg: Columbia University - Mailman School of Public Health, Hospital for Special Surgery, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Binghamton University,
Abstract
Association of omeract core domains of pain and function with patient satisfaction after total joint replacementOrg: Hospital for Special Surgery, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, University of Alabama, Birmingham, AL,